119 related articles for article (PubMed ID: 8276056)
1. Changes in plasma and urinary 11-dehydrothromboxane B2 in healthy subjects produced by oral CS-518, a novel thromboxane synthase inhibitor.
Uematsu T; Takasaki W; Kosuge K; Wada K; Matsuno H; Tanaka Y; Yamamura N; Nakashima M
Eur J Clin Pharmacol; 1993; 45(3):283-6. PubMed ID: 8276056
[TBL] [Abstract][Full Text] [Related]
2. Superiority of plasma 11-dehydro-TXB2 to TXB2 as an index of in vivo TX formation in rabbits after dosing of CS-518, a TX synthase inhibitor.
Takasaki W; Nakagawa A; Asai F; Ushiyama S; Sugidachi A; Matsuda K; Oshima T; Tanaka Y
Thromb Res; 1993 Jul; 71(1):69-76. PubMed ID: 8367836
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic profiles of CS-518, a selective, long-lasting thromboxane synthase inhibitor, after single and multiple oral administration to healthy volunteers.
Uematsu T; Nagashima S; Inaba H; Mizuno A; Kosuge K; Nakashima M
J Clin Pharmacol; 1994 Jan; 34(1):41-7. PubMed ID: 8132850
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers.
Uematsu T; Kosuge K; Umemura K; Nakano M; Terakawa M; Nakashima M
J Pharm Pharmacol; 1996 Apr; 48(4):380-5. PubMed ID: 8794987
[TBL] [Abstract][Full Text] [Related]
5. Tandem mass spectrometric determination of 11-dehydrothromboxane B2, an index metabolite of thromboxane B2 in plasma and urine.
Schweer H; Meese CO; Fürst O; Kühl PG; Seyberth HW
Anal Biochem; 1987 Jul; 164(1):156-63. PubMed ID: 3674365
[TBL] [Abstract][Full Text] [Related]
6. Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey.
Patrignani P; Morton H; Cirino M; Lord A; Charette L; Gillard J; Rokach J; Patrono C
Biochim Biophys Acta; 1989 Jul; 992(1):71-7. PubMed ID: 2752041
[TBL] [Abstract][Full Text] [Related]
7. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
[TBL] [Abstract][Full Text] [Related]
8. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man.
Ciabattoni G; Pugliese F; Davi G; Pierucci A; Simonetti BM; Patrono C
Biochim Biophys Acta; 1989 Jul; 992(1):66-70. PubMed ID: 2752040
[TBL] [Abstract][Full Text] [Related]
9. Enzyme immunoassay of human plasma 11-dehydrothromboxane B2.
Takasaki W; Nakagawa A; Tanaka Y; Nakamura K; Shindo H; Hayashi Y; Yamamoto S
Thromb Res; 1991 Aug; 63(3):331-41. PubMed ID: 1957275
[TBL] [Abstract][Full Text] [Related]
10. Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma.
Obase Y; Shimoda T; Matsuo N; Matsuse H; Asai S; Kohno S
Chest; 1998 Oct; 114(4):1028-32. PubMed ID: 9792572
[TBL] [Abstract][Full Text] [Related]
11. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation.
Catella F; Healy D; Lawson JA; FitzGerald GA
Proc Natl Acad Sci U S A; 1986 Aug; 83(16):5861-5. PubMed ID: 3461463
[TBL] [Abstract][Full Text] [Related]
12. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate.
Asai F; Ito T; Ushiyama S; Matsuda K; Oshima T
Arzneimittelforschung; 1991 May; 41(5):506-10. PubMed ID: 1898421
[TBL] [Abstract][Full Text] [Related]
13. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine.
Ciabattoni G; Maclouf J; Catella F; FitzGerald GA; Patrono C
Biochim Biophys Acta; 1987 Apr; 918(3):293-7. PubMed ID: 3567215
[TBL] [Abstract][Full Text] [Related]
15. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.
Reilly IA; Doran JB; Smith B; FitzGerald GA
Circulation; 1986 Jun; 73(6):1300-9. PubMed ID: 2938849
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of CGS 12970 and inhibition of thromboxane synthesis after oral administration in healthy adults.
Martin LL; Schaffer AV; Piraino A; Linberg L; Singh K; Rakhit A; Douglas FL
Clin Pharmacol Ther; 1991 Apr; 49(4):433-41. PubMed ID: 2015733
[TBL] [Abstract][Full Text] [Related]
17. Effects of a sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans.
Ohnishi A; Ishizaki T; Echizen H; Yasuda K; Fujiwara H; Tanaka T
Clin Pharmacol Ther; 1992 Apr; 51(4):454-64. PubMed ID: 1563215
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
Fitzgerald DJ; Fragetta J; FitzGerald GA
J Clin Invest; 1988 Nov; 82(5):1708-13. PubMed ID: 3183064
[TBL] [Abstract][Full Text] [Related]
19. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904.
Yoshida T; Ichikawa Y; Tojo T; Homma M
Lupus; 1996 Apr; 5(2):129-38. PubMed ID: 8743126
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism.
Patrignani P; Filabozzi P; Catella F; Pugliese F; Patrono C
J Pharmacol Exp Ther; 1984 Feb; 228(2):472-7. PubMed ID: 6537977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
